Dr. O'Brien on CAR T Cells in CLL

Video

Susan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses the potential for CAR T-cell therapy for the treatment of chronic lymphocytic leukemia.

Susan M. O’Brien, MD, a hematologist/oncologist at the University of California, Irvine Health, discusses the potential for chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with chronic lymphocytic leukemia (CLL).

Immunotherapy in the form of CAR T cells has made an impact in hematologic malignancies, particularly in lymphoma and acute lymphocytic leukemia. While this treatment certainly has activity in CLL, it has not proved as effective as it has in those other diseases, O’Brien says.

CAR T-cell therapy works by redirecting the body’s own T cells to attack the cancer; however, in CLL, the patient’s T cells tend to become exhausted and consequently, are unable to function properly. On the other hand, O’Brien notes, “T cell exhaustion” could also be a result of chemotherapy. Researchers could soon overcome this challenge as they move away from chemotherapy regimens to the use of small molecule inhibitors, which are becoming the standard of care in CLL.

O’Brien does not see CAR T cells replacing these inhibitors in the treatment paradigm unless the toxicity profile is lowered. About 25% of patients who receive CAR T cells end up in the intensive care unit because of treatment-related adverse events.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.